• Lilly seeks emergency clearance for Covid-19 monoclonal antibodies on Phase II data

    16 days ago - By MedCity News

    The company announced data on the combination of two antibodies against the SARS-CoV-2 virus, showing significant reductions in viral load compared with placebo. The company has applied for an EUA for LY-CoV555 and will seek an authorization for the combination of that drug with LY-CoV016 next month.
    Read more ...